Trifluridine/tipiracil hydrochloride (S95005)

DRUG2 trials

Sponsors

Institut de Recherches Internationales Servier

Conditions

Metastatic Colorectal Cancer

Phase 3

A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).

CompletedNCT03306394

Institut de Recherches Internationales ServierMetastatic Colorectal Cancer

Start: 2016-10-18End: 2020-11-30Updated: 2024-07-25

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Active, not recruitingNCT03869892

Institut de Recherches Internationales ServierMetastatic Colorectal Cancer

Start: 2019-03-21End: 2026-12-31Updated: 2025-12-22

Related Papers

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

Frontiers in Oncology2025-01-161 citations

Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.

Journal of Clinical Oncology2023-06-015 citations

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy.

2023-01-2710 citations

Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.

2022-12-0233 citations

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

Future Oncology2022-08-305 citations

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

British Journal of Cancer2022-04-1916 citations

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.

2020-06-0128 citations

First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design

Future Oncology2020-01-0923 citations

Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.

Journal of Clinical Oncology2019-01-295 citations

Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting.

Journal of Clinical Oncology2019-01-29

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study

Annals of Oncology2018-06-016 citations